3 Health Care Stocks Dragging The Sector Down

Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer or Stephanie Link.

One out of the three major indices are trading up today with the Dow Jones Industrial Average ( ^DJI) trading down 29 points (-0.2%) at 16,367 as of Wednesday, March 5, 2014, 11:55 AM ET. The NYSE advances/declines ratio sits at 1,229 issues advancing vs. 1,681 declining with 174 unchanged.

The Health Care sector currently sits up 0.1% versus the S&P 500, which is unchanged. On the negative front, top decliners within the sector include XOMA ( XOMA), down 26.1%, Mylan ( MYL), down 1.9%, Biomarin Pharmaceutical ( BMRN), down 1.8%, Shire ( SHPG), down 1.4% and Fresenius Medical Care AG & Co. KGaA ( FMS), down 1.3%. Top gainers within the sector include Boston Scientific Corporation ( BSX), up 1.1%, Express Scripts ( ESRX), up 0.9%, Regeneron Pharmaceuticals ( REGN), up 0.8%, Celgene Corporation ( CELG), up 0.7% and AbbVie ( ABBV), up 0.7%.

TheStreet would like to highlight 3 stocks pushing the sector lower today:

3. Endo International ( ENDP) is one of the companies pushing the Health Care sector lower today. As of noon trading, Endo International is down $2.83 (-3.6%) to $75.15 on heavy volume. Thus far, 2.2 million shares of Endo International exchanged hands as compared to its average daily volume of 2.1 million shares. The stock has ranged in price between $74.71-$78.37 after having opened the day at $78.20 as compared to the previous trading day's close of $77.98.

Endo Health Solutions Inc. provides specialty healthcare solutions in the United States and internationally. Endo International has a market cap of $8.9 billion and is part of the drugs industry. Shares are up 13.9% year-to-date as of the close of trading on Tuesday. Currently there are 8 analysts that rate Endo International a buy, 1 analyst rates it a sell, and 8 rate it a hold.

TheStreet Ratings rates Endo International as a hold. The company's strengths can be seen in multiple areas, such as its solid stock price performance, good cash flow from operations and expanding profit margins. However, as a counter to these strengths, we also find weaknesses including deteriorating net income, generally higher debt management risk and disappointing return on equity. Get the full Endo International Ratings Report now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

2. As of noon trading, AstraZeneca ( AZN) is down $0.37 (-0.5%) to $67.62 on light volume. Thus far, 497,529 shares of AstraZeneca exchanged hands as compared to its average daily volume of 2.5 million shares. The stock has ranged in price between $67.45-$67.84 after having opened the day at $67.51 as compared to the previous trading day's close of $67.99.

AstraZeneca PLC engages in the discovery, development, and commercialization of prescription medicines for cardiovascular, gastrointestinal, neuroscience, infection, oncology, and respiratory and inflammation diseases worldwide. AstraZeneca has a market cap of $84.1 billion and is part of the drugs industry. Shares are up 12.7% year-to-date as of the close of trading on Tuesday. Currently there are 2 analysts that rate AstraZeneca a buy, 1 analyst rates it a sell, and 4 rate it a hold.

TheStreet Ratings rates AstraZeneca as a buy. The company's strengths can be seen in multiple areas, such as its largely solid financial position with reasonable debt levels by most measures and solid stock price performance. We feel these strengths outweigh the fact that the company has had sub par growth in net income. Get the full AstraZeneca Ratings Report now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

1. As of noon trading, Jazz Pharmaceuticals ( JAZZ) is down $3.72 (-2.3%) to $157.00 on average volume. Thus far, 613,859 shares of Jazz Pharmaceuticals exchanged hands as compared to its average daily volume of 1.1 million shares. The stock has ranged in price between $155.85-$158.50 after having opened the day at $157.79 as compared to the previous trading day's close of $160.72.

Jazz Pharmaceuticals Public Limited Company, a specialty biopharmaceutical company, engages in the identification, development, and commercialization of pharmaceutical products for various medical needs in the United States, Europe, and other countries. Jazz Pharmaceuticals has a market cap of $9.1 billion and is part of the drugs industry. Shares are up 23.5% year-to-date as of the close of trading on Tuesday. Currently there are 10 analysts that rate Jazz Pharmaceuticals a buy, no analysts rate it a sell, and 1 rates it a hold.

TheStreet Ratings rates Jazz Pharmaceuticals as a buy. The company's strengths can be seen in multiple areas, such as its robust revenue growth, largely solid financial position with reasonable debt levels by most measures, notable return on equity, expanding profit margins and good cash flow from operations. We feel these strengths outweigh the fact that the company is trading at a premium valuation based on our review of its current price compared to such things as earnings and book value. Get the full Jazz Pharmaceuticals Ratings Report now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

If you are interested in one of these 3 stocks, ETFs may be of interest. Investors who are bullish on the health care sector could consider Health Care Select Sector SPDR ( XLV) while those bearish on the health care sector could consider ProShares Ultra Short Health Care ( RXD).

null

More from Markets

Dow Drops Over 100 Points on Trade War Worries

Dow Drops Over 100 Points on Trade War Worries

Video: Athens Stock Exchange CEO on What's Next for Greece's Debt Woes

Video: Athens Stock Exchange CEO on What's Next for Greece's Debt Woes

What Angela Merkel's Uncertain Political Future Means for Greece's Debt Woes

What Angela Merkel's Uncertain Political Future Means for Greece's Debt Woes

3 Must Reads on the Market From TheStreet's Top Columnists

3 Must Reads on the Market From TheStreet's Top Columnists

Goldman Is Bullish on Oil, Sees Demand Outweighing Inventory Concern

Goldman Is Bullish on Oil, Sees Demand Outweighing Inventory Concern